We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Caprion Announces Expansion of Biomarker Discovery Collaboration with Vertex

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Caprion Announces Expansion of Biomarker Discovery Collaboration with Vertex"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Caprion Pharmaceuticals Inc.'s Applied BioMedicine group has announced an expansion of a previously established biomarker research collaboration with Vertex Pharmaceuticals Incorporated.

The initial collaboration with Vertex was announced in March 2006. The expanded collaboration will continue to apply Caprion's CellCarta® proteomics biomarker technology across preclinical and clinical development activities being conducted by Vertex.

"We believe this expanded collaboration reflects the interest of biotechnology companies to integrate biomarker discovery efforts into major drug development programs," noted Dr. Daniel Chelsky, Executive Vice-President and Chief Scientific Officer at Caprion.

"Caprion is pleased with the progress made under the original collaboration with Vertex, and we look forward to further broadening the collaboration in the coming months."